Pharma pivots to pipelines and M&A as patent cliff hits — Novo Nordisk in spotlight

Drugmakers’ playbook: Pipelines, M&A and the looming patent cliff

European pharmaceutical groups are shifting strategy as a wave of patent expiries forces the industry to prioritise pipelines and business development over near‑term sales protection. Companies face what executives call a “patent cliff” in key markets, and groups with broad portfolios are racing to show that new drugs and strategic deals will offset losses when best‑selling products lose exclusivity. The dynamic is acutely relevant to diabetes and obesity specialists such as Novo Nordisk, whose future growth depends on maintaining momentum in GLP‑1s while expanding into adjacent indications and geographies.

Novo Nordisk and its peers are increasingly couching growth plans around late‑stage assets and bolt‑on acquisitions rather than solely internal R&D timelines. Management teams stress “strategic fit” when evaluating targets, with a mix of smaller, early‑stage buys and the occasional larger, late‑stage deal emerging as the preferred route to shore up near‑term revenues. For firms focused on metabolic diseases, securing complementary assets and manufacturing scale becomes a competitive imperative as rivals seek to close revenue gaps created by falling exclusivity elsewhere in their portfolios.

Executives and advisers tell investors that 2026 will be a litmus test for these tactics, with company pipelines, manufacturing readiness and regulatory timing set to determine which strategies succeed. For Novo Nordisk, the emphasis remains on converting recent commercial success into sustainable franchises by advancing registrations, broadening label claims and, where necessary, augmenting the pipeline through targeted acquisitions or partnerships. The industry’s collective moves now aim to demonstrate that long‑term growth is not solely dependent on a handful of blockbusters.

Leadership shakeups underscore the urgency

The pressure to deliver new revenue is reshaping executive boards: Sanofi’s abrupt CEO departure this season illustrates how tolerance for slow R&D returns is low. Management changes across Europe’s largest drugmakers reinforce that meeting pipeline milestones and executing business‑development plans are central to boardroom survival.

Policy and market context shape the timetable

Regulatory and pricing developments, including political deals reached with the U.S. administration last year, are poised to influence launches, margins and M&A appetite in 2026. Analysts say the coming year will clarify how pricing rules and prior agreements affect drug launches and valuations across Europe and the United States.